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Traumatic brain injury (TBI) is a risk factor for neurodegenerative disease, including chronic 
traumatic encephalopathy (CTE). Preliminary consensus criteria define the pathognomonic 
lesion of CTE as patchy tau pathology within neurons and astrocytes at the depths of cortical 
sulci. However, the specific tau isoform composition and post-translational modifications in 
CTE remain largely unexplored. Using immunohistochemistry, we performed tau 
phenotyping of CTE neuropathologies and compared this to a range of tau pathologies, 
including Alzheimer’s disease, primary age-related tauopathy (PART), aging-related tau 
astrogliopathy (ARTAG) and multiple subtypes of frontotemporal lobar degeneration with tau 
inclusions (FTLD-Tau). Cases satisfying preliminary consensus diagnostic criteria for CTE 
neuropathologic change (CTE-NC) were identified (athletes, n=10; long-term survivors of 
moderate or severe TBI, n=4) from the Glasgow TBI Archive and Penn Neurodegenerative 
Disease Brain Bank. In addition, material from a range of autopsy-proven aging-associated 
and primary tauopathies in which there was no known history of exposure to TBI was 
selected as non-injured controls (n=32). Each case was then stained with a panel of tau 
antibodies specific for phosphoepitopes (PHF1, CP13, AT100, pS262), microtubule-binding 
repeat domains (3R, 4R), truncation (Tau-C3) or conformation (GT-7, GT-38) and the extent 
and distribution of staining assessed. Cell types were confirmed with double 
immunofluorescent labeling. Results demonstrate that astroglial tau pathology in CTE is 
comprised of 4R-immunoreactive thorn-shaped astrocytes, echoing the morphology and 
immunophenotype of astrocytes encountered in ARTAG. In contrast, neurofibrillary tangles 
of CTE contain both 3R and 4R tau, with post-translational modifications and conformations 
consistent with Alzheimer’s disease and PART. Our observations establish that the astroglial 
and neurofibrillary tau pathologies of CTE are phenotypically distinct from each other and 
recapitulate the tau immunophenotypes encountered in aging and Alzheimer’s disease. As 
such, the immunohistochemical distinction of CTE neuropathology from other mixed 3R/4R 
tauopathies of AD and aging may rest solely on the pattern and distribution of pathology. 
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There is increasing recognition of the association between exposure to traumatic brain injury 
(TBI) and risk of subsequent neurodegenerative disease, in particular chronic traumatic 
encephalopathy (CTE).  First described as the “punch drunk syndrome” in 1928 (Martland, 
1928) and later “dementia pugilistica” (DP) (Millspaugh, 1937), progressive 
neurodegeneration in the context of TBI was historically considered a consequence of 
participation in boxing. However, more recent descriptions of the neurodegenerative 
pathology of DP, now recognized as CTE, in non-boxer athletes exposed to repetitive mild 
TBI (Corsellis et al., 1973; Geddes et al., 1999; Omalu et al., 2011; Saing et al., 2012; 
McKee et al., 2013; Smith et al., 2013; McKee et al., 2016; Stewart et al., 2016; Johnson et 
al., 2017; Mez et al., 2017; Wilson et al., 2017; Lee et al., 2019; Smith et al., 2019) and late 
survivors of a single moderate or severe TBI (Johnson et al., 2012; Kenney et al., 2018; 
Zanier et al., 2018) have brought the potential lifelong consequences of TBI exposure to 
wider attention. Nevertheless, the current consensus criteria for CTE neuropathological 
assessment remain preliminary and there are few detailed accounts of its similarities and 
differences with other tauopathies. 
 
While intraneuronal tau aggregates in the form of neurofibrillary tangles (NFTs) have long 
been described in DP/CTE, more recent studies also note the presence of pathological 
astroglial tau accumulation in the form of thorn-shaped astrocytes (TSA) (Ikeda et al., 1995; 
Ikeda et al., 1998; Schmidt et al., 2001; McKee et al., 2009; Saing et al., 2012; McKee et al., 
2013; Kanaan et al., 2016; Mez et al., 2017). Indeed, the importance of this mixed neuronal 
and astroglial pathology in CTE is reflected in preliminary consensus diagnostic criteria for 
the disease, which propose the pathognomonic lesion as “phosphorylated-tau aggregates in 
neurons, astrocytes, and cell processes around small vessels in an irregular pattern at the 
depths of the cortical sulci” (McKee et al., 2016). This sulcal lesion is suggested as 
sufficiently unique to distinguish CTE from other tau associated neurodegenerative diseases 
including Alzheimer disease (AD), frontotemporal lobar degeneration characterized by tau 
inclusions (FTLD-tau) - including progressive supranuclear palsy (PSP), corticobasal 
degeneration (CBD) and Pick’s disease (PiD) (Cairns et al., 2007; Montine et al., 2012; 
Kovacs, 2015), as well as the pathologies of primary age-related tauopathy (PART) and 
aging-related tau astrogliopathy (ARTAG) (Crary et al., 2014; Kovacs et al., 2016).  
 
However, there remains debate regarding whether tau found at sulcal depths is solely found in 
individuals with a history of head impacts, or if it can occur in individuals with no contact 
sport or TBI history (Iverson et al., 2019).  
 
Beyond the potentially unique distribution of tau pathologies in CTE, little is known 
regarding tau composition and post-translational modifications. Of the six tau isoforms 
containing either 3 or 4 microtubule-binding repeat domains (3R vs 4R tau) (Goode et al., 
2000), NFTs in AD and PART contain both 3R and 4R tau (Espinoza et al., 2008; Santa-
Maria et al., 2012; Crary et al., 2014). In contrast, while the Pick bodies and ramified 
astrocytes of PiD contain primarily 3R tau (Irwin et al., 2016), the astrocytic tau pathologies 
of PSP, CBD and ARTAG are comprised of 4R tau (Cairns et al., 2007; Ferrer et al., 2014).  
Regarding CTE pathology, biochemical analysis of material from two former boxers with 
DP/CTE reported NFTs comprising both 3R and 4R tau, similar to AD (Schmidt et al., 2001; 
McKee et al., 2013).  A further case series indicates that tau in CTE displays conformations 
and phosphoepitopes comparable to those observed early in NFT maturation in AD (Kanaan 
et al., 2016). Nonetheless, comprehensive assessment of the phosphorylation, truncation and 
conformation of both glial and neuronal tau pathologies in CTE has not previously been 
assessed, particularly within the context of other established tauopathies (Ferrer et al., 2014; 
Kovacs, 2015; Irwin et al., 2016).  
 
Here, we report immunohistochemical observations on extensive tau phenotypic analysis of 
autopsy-derived material from individuals with known CTE neuropathologies and histories of 
exposure to either repetitive sport-related mild TBI, or moderate/severe TBI, when compared 
to aging-associated and primary neurodegenerative tauopathies. Specifically, applying 
antibodies specific for tau isoform, multiple phosphoepitopes, caspase-mediated truncation, 
and novel monoclonal antibodies capable of differentiating 3R/4R tau in AD from the 
conformationally-distinct FTLD-tau (Gibbons et al., 2018; Gibbons et al., 2019), we 
demonstrate that while the NFTs and astroglial tau pathologies of CTE differ 




MATERIALS AND METHODS 
Cohort Demographics 
All cases were obtained from the Glasgow TBI Archive, Department of Neuropathology, 
Queen Elizabeth University Hospital, Glasgow, UK or the University of Pennsylvania Center 
for Neurodegenerative Disease Research (CNDR) Brain Bank, Philadelphia, PA, USA. Brain 
tissue was acquired by means of planned donation or at routine diagnostic autopsy. Ethical 
approval for use of tissue in this study was provided by the West of Scotland Research Ethics 
Committee (Project ID 225271); and the Greater Glasgow and Clyde Biorepository 
(Application Number 340), as well as the institutional review board of the University of 
Pennsylvania.  
 
Cases were selected with a history of participation in contact sports: American football (n=4), 
rugby (n=3), soccer (n=2), or boxing (n=1), or a remote history of single moderate or severe 
TBI caused by assault (n=1), motor vehicle collision (n=1) or fall (n=1). One additional case 
sustained one mild and one moderate TBI caused by falls (n=1). Cases were selected with 
previously confirmed CTE neuropathologic change (CTE-NC) (Lee et al., 2019) based on the 
preliminary consensus criteria for the neuropathological evaluation of CTE (McKee et al., 
2016).  Notably, in addition to CTE neuropathology, multiple cases also displayed co-morbid 
neuropathologies (n=8) as has previously been reported (Lee et al., 2019). Clinical, 
demographic and neuropathologic information, including integrated clinicopathologic 
diagnoses (Lee, 2018) for all cases is presented in Table 1.   
 
To permit comparisons of CTE tau pathologies with those of established neurodegenerative 
disease, material from patients without documented history of TBI or participation in contact 
sport was selected that met neuropathological criteria for the diagnosis of AD (Braak Stage V 
or VI; n=6) or FTLD-tau as Pick’s disease (PiD) (n=6), PSP (n=6), or CBD (n=6). In 
addition, non-demented controls without history of TBI and with known aging-related tau 
pathologies were selected including; PART (n=1), ARTAG and PART (n=3) and ARTAG 
with low AD neuropathologic change (n=4) (Cairns et al., 2007; Montine et al., 2012; Crary 
et al., 2014; Kovacs et al., 2016; McKee et al., 2016) (Table 1).  
 
Brain Tissue Handling 
 
Whole brains from the Glasgow TBI Archive were fixed in 10% formol saline at autopsy for 
a minimum of two weeks prior to dissection. Standardized anatomical sampling, tissue 
processing and paraffin embedding were performed as previously described (Graham et al., 
1995). From the University of Pennsylvania CNDR Brain Bank, tissue blocks cut from fresh 
brains were fixed overnight in 70% ethanol and 150mMol sodium chloride or 10% neutral 
buffered formalin and processed to paraffin as previously described (Toledo et al., 2014).  
From each case, 8µm tissue sections were prepared from regions with stereotypical CTE 
neuropathology at the depths of cortical sulci. For comparison, regions displaying hallmark, 
disease-specific pathologies were selected from non-trauma control cases of AD (NFTs), 
PART (NFTs), PiD (Pick bodies and ramified astrocytes), PSP (tufted astrocytes), CBD 
(astrocytic plaques) and ARTAG (TSA) (Cairns et al., 2007; Montine et al., 2012; Crary et 
al., 2014; Kovacs et al., 2016). 
 
Single Immunohistochemical Labeling 
Serial tissue sections for all cases were subjected to deparaffinization and rehydration to H2O 
before being immersed in 3% aqueous H2O2 (15 minutes) to quench endogenous peroxidase 
activity. Antigen retrieval was performed via microwave pressure cooker in either Tris/EDTA 
or citrate buffer, with or without formic acid pre-treatment, as optimized for each antibody 
(Table 2). Sections were blocked using normal horse serum (Vector Labs) in Optimax buffer 
(BioGenex) for 30 minutes followed by incubation in the primary antibody overnight at 4°C. 
Specifically, a panel of tau antibodies (Table 2) was applied targeting multiple 
phosphoepitopes including S202 (CP13) (Jicha et al., 1999), S396/S404 (PHF1) (Greenberg 
et al., 1992; Otvos et al., 1994), S212/T214 (AT100) (Hoffmann et al., 1997; Zheng-
Fischhofer et al., 1998) and S262; 3 or 4 microtubule-binding domain repeats (RD3 & RD4) 
(de Silva et al., 2003); caspase-cleaved tau at Asp421 (Tau-C3) (Gamblin et al., 2003). In 
addition we applied the recently characterized antibodies GT-7 & GT-38 (Gibbons et al., 
2018; Gibbons et al., 2019). Evidence from co-immunofluorescence studies in human tissue 
with FTLD-tau and AD-tau suggest that GT-38 requires the presence of both 3R and 4R tau. 
Moreover, it was demonstrated that GT-38 binding requires a pathological conformation of 
AD-tau since chemical denaturation leads to a reduction of GT-38 binding (Gibbons, G. S. et 
al. 2018 J Neuropathol Exp Neurol 77, 216-228).	 
 
After rinsing, sections were incubated in a biotinylated universal secondary antibody (Vector 
Labs) for 30 minutes, followed by the avidin-biotin complex for 30 minutes (Vector Labs). 
 
Visualization was achieved using the DAB peroxidase substrate kit (Vector Labs). Sections 
were counterstained with hematoxylin, followed by rinsing, dehydration, and coverslipping 
using cytoseal 60.  Tissue sections from a case with neuropathologically confirmed AD were 
included as a positive control in all staining procedures. Omission of the primary antibody 
using the same AD case was performed in parallel to control for non-specific binding. 
Notably, 3 cases (Table 3: Cases 9 (CTE neuropathology), 11 (CTE neuropathology) and 15 
(ARTAG/PART)) failed to demonstrate immunoreactivity to antibodies specific for 3R and 
4R tau due to fixation sensitivity, as has been reported previously with these antibodies 
(Espinoza et al., 2008; Ferrer et al., 2014).  
 
Double Immunofluorescent Labeling  
Serial tissue sections from a subset of cases (CTE n=5, ARTAG n=2, AD n=2) were selected 
for double labeling immunofluorescence to confirm and validate morphological identification 
of cell types (astrocytes versus neurons) as identified by both PHF1 and GT-38. Specifically, 
sections were labelled with combinations of tau antibodies (PHF1 or GT-38) and cell-type 
specific markers, namely MAP2 for neurons and GFAP for astrocytes using established 
protocols (Johnson et al., 2016). Briefly, following deparaffinization and rehydration, antigen 
retrieval was performed as described above and tissue blocked in the relevant species-specific 
serum (1%) (Vector Labs). Primary antibodies were applied serially for 20 hours (4oC) 
specific for PHF1 (1:100) or GT-38 (1:100), followed by glial fibrillary acidic protein 
(GFAP) (Abcam, Cambridge, MA; 1:200) or the microtubule-associated protein 2 (MAP2) 
(Abcam, Cambridge, MA; 1:200). After rising, the corresponding Alexa Fluor (Invitrogen, 
Carlsbad, CA) secondary antibody was applied at 1:500 in a 2% species-specific blocking 
solution for 2 hours at room temperature. Serial sections of positive control tissue (AD) were 
subjected to the entire procedure with omission of subsets of primary antibodies to control for 
non-specific immunofluorescence. Following rinsing, all double fluorescent-immunolabeled 
sections were incubated in TrueView autofluorescence quenching reagent (Vector Labs) for 5 
minutes at room temperature before being rinsed and coverslipped using Vectashield 
mounting medium (Vector Labs). 
 
Analysis of Immunohistochemical Findings 
Using a standardized approach, the extent of immunoreactivity for each antibody was scored 
relative to that observed using an index antibody in each individual case, as has been 
described previously (Ferrer et al., 2014). Specifically, a semi-quantitative score was used to 
 
denote the extent of immunoreactivity relative to that of PHF1 as: absent or nearly absent 
(<5% concordance with the extent of PHF1 immunoreactivity): minimal (5-30% 
concordance); moderate (30-70% concordance); or extensive (>70% concordance). PHF1 was 
selected as the index antibody given its widely reported use for the identification of tau 
pathologies across neurodegenerative diseases and recommended use for the identification of 
CTE pathology in preliminary consensus criteria (McKee et al., 2016). Under this protocol, 
scoring does not reflect the number of positive cells or permit comparisons of the extent of 
pathology between cases, but rather reflects the relative extent to which a particular antibody 
recognizes the burden of tau pathology as identified via PHF1 in each field of interest. Glial 
versus neuronal pathologies were distinguished based on characteristic cellular morphologies. 
A subset of sections was reviewed and scored independently by two observers (JDA & VEJ), 
with good interrater reliability (Cohen’s Kappa 0.71). Where there was a discrepancy in 




Consistent with prior descriptions of CTE neuropathology (McKee et al., 2016), each TBI 
case displayed PHF1 positive neurons and astrocytes in a patchy and perivascular distribution 
concentrated at the depths of cortical sulci (Fig 1). Astrocytes typically displayed thorn-
shaped morphologies, with short, thickened processes (Ikeda et al., 1995; Kovacs et al., 2016; 
Kovacs et al., 2017a), frequently in the immediate subpial region at the sulcal depth, in 
addition to being observed in a patchy and perivascular distribution within deeper layers of 
cortex. Neuronal tau pathology at the depths of cortical sulci in cases with CTE 
neuropathology displayed the morphology of NFTs, consistent with historical and 
contemporary descriptions (Corsellis et al., 1973; Geddes et al., 1996; Geddes et al., 1999; 
Omalu et al., 2005; McKee et al., 2009; McKee et al., 2013; McKee et al., 2016). The 
distinctive cellular morphologies of CTE astrocytes and neurons were confirmed via double 
immunofluorescence labeling on a subset of cases as described. Specifically, NFTs identified 
via PHF1 co-localized with MAP2, but not GFAP. Conversely, thorn-shaped astrocytes 
(TSA) were observed to co-localize with GFAP but not MAP2, consistent with findings in 
AD and ARTAG (Figs 7, S1, S2).  
 
As expected, neurodegenerative disease controls displayed the hallmark and cell-specific tau 
pathologies characteristic for each diagnosis as identified by PHF1. Specifically, FTLD-tau 
 
controls demonstrated Pick bodies and, in some cases, ramified astrocytes in PiD, tufted 
astrocytes in PSP and astrocytic plaques in CBD.  AD cases had NFTs in a bilaminar cortical 
distribution in addition to diffuse neuritic threads. Controls with aging related pathologies 
displayed limited cortical NFT pathology consistent with PART or low AD neuropathological 
change, as well as TSA consistent with ARTAG in white matter, perivascular, gray matter, 
subpial, or subependymal distributions.  
 
Astroglial pathology of CTE contains 4R tau only, whereas neurofibrillary tangles are 
comprised of both 3R and 4R tau 
Tau positive astrocytes within regions of CTE neuropathology were composed of 4R tau only 
in virtually all cases (Figs 2 & 3; Table 3). Specifically, in cases demonstrating adequate 
immunoreactivity, robust and consistent immunoreactivity to RD4 was observed in astrocytes 
within the subpial region, as well as those extending to deeper cortical layers. In contrast, 
astrocytic immunoreactivity to the RD3 antibody was absent in all but two cases where just 
minimal staining was observed. Notably, TSA of CTE were morphologically 
indistinguishable from those within non-injured control cases with ARTAG, which were also 
comprised almost entirely of 4R tau, consistent with previous reports (Lopez-Gonzalez et al., 
2013; Ferrer et al., 2018) (Fig 3). Several cases with CTE neuropathology displayed TSA 
elsewhere in the tissue sections examined, including within subcortical white matter, 
subependymal, and subpial regions, in keeping with descriptions of ARTAG. These 
astrocytes were morphologically indistinguishable from those in the sulcal depths associated 
with stereotypical CTE neuropathology and displayed the same pattern of selective 4R tau 
immunoreactivity.  
In contrast, ramified astrocytes of Pick’s disease were comprised of 3R tau, with a subset of 
cells in just one of the six cases also displaying 4R immunoreactivity, as has been reported 
previously in a subset of cases (Arai et al., 2001; Ferrer et al., 2014; Irwin et al., 2016). The 
tufted astrocytes in PSP and astrocytic plaques in CBD controls displayed immunoreactivity 
for 4R tau only (Fig 3). 
 
While astrocytes in CTE were typically 4R tau-immunoreactive / 3R tau-negative, NFTs in 
these regions were immunoreactive for both 3R and 4R tau isoforms, similar to those of AD 
and PART (Fig 2; Table 3) and distinct from Pick bodies (3R positive only) (Fig 2).  
 
 
Post-translational modification of tau in CTE neuropathology is consistent with ARTAG 
and AD 
The post-translational modifications of tau within astrocytes and NFTs of CTE were observed 
to recapitulate those of ARTAG and AD with respect to all antibodies assessed. Specifically, 
tau immunoreactive astrocytes in CTE exhibited phosphorylation at residues S202 (CP13), 
S212/T214 (AT100), S262, and S396/S404 (PHF1) (Fig 4, Table 4). Typically, CP13, 
AT100, and PHF1 displayed dense cytoplasmic staining throughout the cell body.  In 
contrast, pS262 immunoreactivity displayed both robust and confluent immunoreactivity (Fig 
4), as well as a more dot-like pattern of immunoreactivity in a subset of cases/cells that was 
often concentrated in the peripheral processes of the astrocyte (Fig S3).  Caspase-mediated 
truncation at D421 (Tau-C3), however, was virtually never seen in astrocytes in CTE, with 
just minimal cells observed in a single case. Again, all findings were consistent across TSA in 
subpial and deeper cortical astrocytes within the sulcal depth. This profile of staining was 
also indistinguishable from that observed in non-injured, ARTAG control cases (Fig 4). In 
contrast with the astroglial pathologies of CTE, ARTAG, PiD and CBD, which did not 
typically demonstrate immunoreactivity to Tau-C3, subsets of tufted astrocytes in two PSP 
cases demonstrated Tau-C3 immunoreactivity, consistent with previous reports (Fig 4) 
(Ferrer et al., 2014).  
 
Notably, NFTs in CTE also displayed robust cytoplasmic immunoreactivity for all tau 
phosphoepitopes including S202 (CP13), S212/T214 (AT100), S262 and S396/S404 (PHF1) 
(Fig 5). Moreover, a sub-population of NFTs in CTE demonstrated evidence of caspase-
mediated truncation of tau at D421 (Tau-C3) (Fig 5), consistent with that observed previously 
(Kanaan et al., 2016), and in AD here and in prior reports (Gamblin et al., 2003). 
 
FTLD-tau controls were consistent with prior characterizations performed using these 
antibodies (Buee and Delacourte, 1999; Guillozet-Bongaarts et al., 2007; Ferrer et al., 2014), 
and displayed immunoreactivity for antibodies recognizing phosphorylation at residues S202 
(CP13), S212/T214 (AT100), S262 (p262), and S396/S404 (PHF1). Notably, in one case of 
PiD, Picks bodies appeared weakly immunoreactive for p262 (Fig 5). In contrast, neurons 
were otherwise negative for tau p262 in all other five PiD cases. Notably, previous work has 
demonstrated conflicting results with regard to pS262 immunoreactivity in PiD (Probst et al., 
1996; Delacourte et al., 1998; Ferrer et al., 2002; Zhukareva et al., 2002; Irwin et al., 2016; 
Falcon et al., 2018). However, greater immunoreactivity has been reported in ethanol versus 
 
formalin fixed tissue (Irwin et al., 2016), consistent with our observations. Moreover, the 
intensity of pS262 immunoreactivity was reported as greater in cases with 4R tau inclusions 
(Zhukareva et al., 2002). 
 
Neurofibrillary tangles, but not astrocytes, in CTE show a similar conformational profile to 
those in AD  
Recently developed conformation-selective antibodies, GT-7 and GT-38, have been shown to 
detect a conformation dependent epitope present in tau within the inclusions of AD requiring 
both 3R and 4R tau, but not the 3R or 4R tau-only inclusions of other primary tauopathies, 
with both antibodies labeling AD-tau in a phosphorylation-independent manner (Gibbons et 
al., 2018; Gibbons et al., 2019). In CTE neuropathology, both GT-7 and GT-38 showed 
moderate to strong labelling of NFTs at the depths of sulci, consistent with AD (Fig 6, Table 
3). However, in contrast with NFTs, astrocytes within CTE were negative for GT-7 or GT-38 
in all but four cases in which there was very occasional and minimal positivity to one or the 
other antibody (Table 3). These cells did not differ in their morphology, and no notable 
differences in fixation, clinical history or anatomic distribution distinguished them from the 
rest of the cohort. Double immunofluorescence labeling in a subset of cases confirmed 
neuron-specific colocalization of GT-38 with MAP-2, and an absence of co-localization with 
GFAP (Fig 7, S2).  
As anticipated, NFTs in non-injured AD and PART cases demonstrated robust 
immunoreactivity for both antibodies (Fig 6, Table 3), while Pick bodies and the glial 
profiles of ARTAG, CBD and PSP were negative for both GT-7 and GT-38 (Fig 6). Notably, 
the ramified astrocytes within the single PiD case that were immunoreactive for both 3R and 
4R tau, were not immunoreactive for GT-7 or GT-38. Among TBI cases with co-morbid 
diagnoses of FTLD-tau, both GT-7 and GT-38 antibodies stained the characteristic NFTs of 





Here, we performed immunohistochemical characterization of tau phenotypes within the 
cellular constituents of CTE in patients with known exposure to repetitive mild TBI or 
moderate/severe TBI.  Intriguingly, it was found that the tau species within NFTs and 
immediately adjacent astrocytes in CTE are phenotypically distinct. Specifically, the NFTs of 
 
CTE displayed an immunophenotype that mirrored that seen in AD or PART, including being 
both 3R and 4R immunoreactive and positive for antibodies previously shown to bind to a 
conformation dependent epitope present within the tau inclusions of AD. In contrast, the 
astroglial component of CTE was solely 4R immunoreactive and without evidence of AD 
conformation, which was indistinguishable from ARTAG. Notably, while the neuronal and 
glial pathologies of CTE showed similarity with those of AD, PART and ARTAG, they were 
distinct from those of the primary FTLD tauopathies of PiD, CBD and PSP. As such, our data 
suggest that while pattern and distribution of involvement might be distinct, the tau 
pathologies of CTE show considerable overlap with the immunoreactivity profiles of both 
aging-related tau pathologies and AD.  
 
Typically, we observed tau immunoreactive astrocytes within CTE to have the characteristic 
morphology of TSA, in keeping with those encountered in ARTAG, in both the non-injured 
control material studied here and in multiple other reports (Lopez-Gonzalez et al., 2013; 
Kovacs et al., 2016; Kovacs et al., 2017a; Kovacs et al., 2018a). Notably, TSA have long 
been described in material from patients with and without concomitant neurodegenerative 
disease. In particular, their appearance in association with increased age led to the recognition 
of the specific entity recently defined as ARTAG, wherein TSA are described in subpial, 
subependymal and perivascular distributions (Ikeda et al., 1995; Ikeda, 1996; Ikeda et al., 
1998; Schultz et al., 2004; Lace et al., 2012; Kovacs et al., 2013; Kovacs et al., 2016). While 
the clinical significance of ARTAG has yet to be fully explored (Kovacs et al., 2017b), the 
morphological resemblance between astrocytes immunoreactive for phosphorylated tau in 
both CTE and ARTAG raises the possibility that these entities share common pathogenic 
mechanisms (Kovacs et al., 2016; Liu et al., 2016; Kovacs et al., 2017b; Goldfinger et al., 
2018; Kovacs et al., 2018a; Forrest et al., 2019). Our data demonstrate that the astrocytes of 
CTE and ARTAG not only share similar morphologies, but display indistinguishable tau 
immunophenotypes with respect to the panel of antibodies applied. Specifically, consistent 
with previous reports characterizing ARTAG (Kovacs et al., 2016; Ferrer et al., 2018) and 
one limited description in CTE (McKee et al., 2013), TSAs in CTE were typically 4R tau-
immunoreactive/3R tau-negative, with only very occasional cells displaying 
immunoreactivity for 3R tau in a subset of cases. Further, astrocytes in CTE demonstrated a 
profile of immunoreactivity for multiple phospho-epitopes of tau consistent with descriptions 
of ARTAG here and previously (Lopez-Gonzalez et al., 2013; Ferrer et al., 2018).  
 
 
Beyond this astroglial pathology, the regionally co-existing NFTs in CTE appeared 
morphologically and phenotypically consistent with those of AD and PART, comprised of 
both 3R and 4R tau, and immunoreactive for tau hyperphosphorylated at multiple phospho-
epitopes, including S202, S212/T214, S262, and S396/S404. Notably, characterization by 
others has highlighted additional shared features of tau including phosphatase-activating 
domain exposed conformation (TNT1 antibody), tau oligomers (TOC1), and truncation at 
D421 (Tau-C3) (Kanaan et al., 2016). Here we demonstrate that a subset of NFTs in AD, 
PART and CTE demonstrate caspase-mediated truncation at D421. Interestingly, Tau-C3 
positivity has previously been reported as relatively sparse in CTE neuropathology when 
compared with AD (Kanaan et al., 2016). However, the diminished total burden of Tau-C3 
immunoreactivity may reflect a virtual absence of immunoreactivity in TSA, as observed 
here. Truncation of tau at D421 has been reported as an early event in the evolution of NFTs 
in AD (Gamblin et al., 2003; Rissman et al., 2004; Cotman et al., 2005), although it may not 
be essential for filament formation (Delobel et al., 2008). Moreover, experimental data 
indicates caspase-mediated truncation may promote polymerization and seeding of full length 
tau (Abraha et al., 2000; Berry et al., 2003; Gamblin et al., 2003; Rissman et al., 2004), as 
well as contribute to neurotoxicity via apoptosis (Fasulo et al., 2000; Chung et al., 2001; 
Fasulo et al., 2005). As such, the relative absence of Tau-C3 immunoreactivity in TSA of 
CTE may have implications as to the potential pathological nature of tau immunoreactive 
TSA in CTE. 
 
The astrocytic tau pathologies of both CTE and ARTAG also failed to display 
immunoreactivity for the recently developed tau antibodies, GT-7 and GT-38, previously 
demonstrated to detect  a conformation-dependent epitope of tau in AD in a phosphorylation-
independent manner (Gibbons et al., 2018; Gibbons et al., 2019). Furthermore, these 
antibodies failed to label pathologies comprised of tau with either 3R or 4R isoforms only 
(Gibbons et al., 2018; Gibbons et al., 2019).  Thus, the observation that both GT-7 and GT-38 
bind to NFTs in CTE, but not sulcal TSA, further supports the observation that astrocytic tau 
is 4R only and differs from that of the adjacent NFTs. Indeed, while the characteristic 
pathologies of FTLD-tau were not immunoreactive for either GT-7 or GT-38, as previously 
characterized in detail (Gibbons et al., 2018; Gibbons et al., 2019), the NFTs of CTE, AD and 
PART were consistently immunoreactive for both. 
 
 
The panel of antibodies examined herein were selected for their previous extensive 
characterization and reported differences across a range of neurodegenerative diseases.  As no 
immunolabel examined thus far can morphologically or phenotypically differentiate 
individual cells in CTE from those of other established tauopathies, the distinguishing 
features of this pathology remain dependent on the overall pattern and distribution of 
pathology when using immunohistochemistry (McKee et al., 2016). Notably, this panel is not 
exhaustive, and the use of immunohistochemistry to explore additional, and potentially 
distinguishing tau phenotypes, including ubiquitination and acetylation, will be important. 
Notably, a recent study based on cryo-electron microscopy (cryo-EM) analysis of temporal 
lobe tissue from 3 cases of known CTE suggests that the tau filament structure of CTE is 
distinct from that of AD (Falcon et al., 2019). However, it is noteworthy that all three cases 
demonstrated clinical or neuropathological evidence of other neurodegenerative disease, 
including Parkinson’s disease, FTLD and/or motor neuron disease, in one instance associated 
with C9orf72 mutation (Falcon et al., 2019). Given the diversity and heterogeneity of co-
morbid pathologies reported with CTE here and elsewhere (Mez et al., 2017; Lee et al., 
2019), it will be important to extend cryo-EM studies to a wider range of trauma-associated 
cases. Nonetheless, these data suggest that while tau in CTE might differ from that of other 
established neurodegenerative disease, in particular AD, this may only be detectable by 
means beyond established immunohistochemical or biochemical approaches.  
 
There is increasing recognition that mixed, often multiple pathologies might co-exist in 
patients with neurodegenerative disease, including in those with TBI-related 
neurodegeneration where CTE might serve as the primary pathology driving disease or as a 
co-morbidity in context of an alternate diagnosis (Lee et al., 2019).  Consistent with this, 
most cases with CTE examined here also met criteria for other tauopathies, including AD, 
PSP, and CBD, as previously reported (Lee et al., 2019). Notably, the morphologies and 
immunophenotype of CTE were highly consistent across cases, regardless of the presence or 
extent of co-morbid disease. Moreover, CTE was consistent in phenotype, regardless of the 
nature of TBI exposure, including in three cases with a remote history of single moderate or 
severe TBI. These cases add to the limited number of described cases of single TBI 
associated with CTE neuropathologies, supporting the assertion that it is exposure to TBI 
rather than severity or number of injuries that serves as the primary risk factor for CTE 
(Smith et al., 2013; Maroon et al., 2015; Smith et al., 2019). 
 
 
Collectively, these data indicate the co-existence of distinct tau phenotypes within neurons 
and astrocytes contributing to CTE neuropathology. Moreover, immunohistochemical 
observations were notably consistent across all cases examined, comprised of diverse TBI 
exposure histories. While criteria for delineating the extent or stage of disease in CTE have 
yet to be adequately defined, future explorations of tau immunophenotype in association with 
disease progression will be of importance to examine. 
While the mechanisms driving tau pathology following TBI exposure remain poorly 
understood, it is possible that the differential neuronal and astrocytic components reflect 
mechanistically independent pathological processes. Curiously, TSA in both ARTAG and 
CTE are frequently observed at brain parenchyma-fluid interfaces, including subpial, 
subependymal and perivascular regions (Ikeda et al., 1995; Geddes et al., 1996; Geddes et al., 
1999; Kovacs et al., 2016; McKee et al., 2016; Kovacs et al., 2018a). Moreover, regional 
correlation of ARTAG with astrocytic expression of connexin-43 and aquaporin 4 has led to 
speculation that blood brain barrier (BBB) dysfunction may be of pathologic significance to 
the development of this pathology (Kovacs et al., 2018b). While BBB dysfunction is 
increasingly recognized as an important acute pathology of TBI, even following concussion 
(Weissberg et al., 2014; Johnson et al., 2018), recent data indicates BBB permeability may 
persist chronically in some individuals after severe TBI (Hay et al., 2015) and has also been 
described in cases of CTE (Doherty et al., 2016). However, a potential mechanistic 
relationship between BBB dysfunction and pathological astrocytic tau accumulation remains 
unexplored.  
 
Here we provide new insights into the nature of tau in CTE neuropathologic change directly 
within the context of other neurodegenerative pathologies. Moreover, these data highlight the 
potential challenges in distinguishing trauma-associated tau pathologies from those of other 
diseases at the individual cell level using immunohistochemistry alone. Nonetheless, 
morphological and phenotypic similarities between tau in CTE and those of ARTAG suggests 
the intriguing possibility of shared pathogenic mechanisms. 
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Figure 1. Sulcal depth astrocytic and neuronal tau pathologies in CTE. (a,b) PHF1 
immunohistochemistry reveals neurofibrillary tangle and thorn-shaped astrocyte pathology 
concentrated at the depths of cortical sulci of a former American football player (Case 3) and 
(c,d) chronic survivor of a single severe TBI (Case 11). (b,d) High magnification images 
from the same sulci showing perivascular pathology comprised of mixed neuronal and 
astrocytic populations consistent with the preliminary diagnostic criteria for CTE. All scale 
bars 100 µm.  
 
Figure 2. 3R versus 4R tau immunoreactivity in CTE, AD, PART and PiD. (a) Sulcal 
depth CTE neuropathology with prominent subpial thorn-shaped astrocytes in addition to 
patchy and perivascular thorn-shaped astrocytes and neurofibrillary tangles within the deeper 
layers of cortex (Case 10; PHF1 staining). (b) Higher magnification of box in (a) displaying 
perivascular astrocytic and neuronal tau pathologies. (c) Immunoreactivity specific for 3R tau 
in the same region as (b) showing perivascular neurofibrillary tangles, but an absence of 
immunoreactivity within astrocytes. (d) In contrast, immunohistochemistry specific for 4R 
tau identified cells with both neuronal and astrocytic morphologies in the same region. (e) 
Consistent with previous descriptions, cases meeting diagnostic criteria for AD (Case 25) and 
PART (Case 15) displayed neurofibrillary tangles in the cortex that were immunoreactive for 
3R and 4R tau. In contrast, Pick bodies of PiD within the dentate granule cells of Case 29 
were composed of only 3R tau. Scale bars a-d 100 µm, e 50 µm. 
 
Figure 3. 3R versus 4R tau immunoreactivity within the astrocytic pathologies of CTE, 
ARTAG, PSP, CBD and PiD. Representative examples of serial sections showing 
 
immunoreactivity specific for 4R tau, but not 3R tau, in the thorn-shaped astrocytes in cases 
of both CTE (Case 6) and ARTAG (Case 21), tufted astrocytes in a case with PSP (Case 35) 
and astrocytic plaques within a case of CBD (Case 41). The ramified astrocytes observed in 
just one case of PiD (case 29) were immunoreactive for 3R and 4R tau. Scale bars 50 µm. 
 
Figure 4. Post-translational modifications of tau within astrocytes in CTE, AD, PART, 
ARTAG, PSP, CBD and PiD. Representative examples of serial sections showing the thorn-
shaped astrocytes of CTE (Case 3) and ARTAG (Case 22),  astrocytic plaques of CBD (Case 
41) and ramified astrocytes in a case of PiD (Case 29)  all displayed robust immunoreactivity 
to phosphoepitope antibodies PHF1, CP13, AT100 and pS262, but not Tau-C3 (truncation at 
D421). In contrast with all other astrocytic tau pathologies examined, the tufted astrocytes of 
PSP in a subset of cases (Case 35 pictured here) were labeled with Tau-C3, indicative of 
truncation as described. Scale bars 50 µm.  
 
Figure 5. Post-translational modifications of tau within neurons in CTE, AD, PART and 
PiD. Representative examples of serial sections showing the neurofibrillary tangles of CTE 
(Case 5), AD (Case 28) and PART (Case 15) with immunoreactivity to the phosphoepitope 
antibodies PHF1, CP13, AT100 and pS262, as well as Tau-C3 indicating truncation at D421. 
In addition, while Pick bodies (Case 29) also demonstrated the same post-translational 
modifications, immunoreactivity to p262 and Tau-C3 was noted in just one case as shown 
here within the dentate granule cells, where immunoreactivity was notably less robust. Scale 
bars 50 µm 
 
Figure 6. Neurofibrillary tangles, but not astrocytes, are immunoreactive for antibodies 
that detect a conformation-dependent epitope of tau in AD. PHF1 immunohistochemistry 
revealed sulcal depth astrocytic and neuronal tau pathology in CTE (Case 8), including 
prominent clusters of perivascular and subpial thorn-shaped astrocytes (top left; black 
arrows). However, GT-7 and GT-38 antibodies labeled neurofibrillary tangles in CTE, but not 
thorn-shaped astrocytes, on serial tissue sections (top middle and top right). GT-7 and GT-38 
reliably detected neurofibrillary tangles in AD (Case 28), but failed to label the characteristic 
pathologies of ARTAG (Case 19), PiD (Case 29), PSP (Case 35) or CBD (Case 41).  




Figure 7. Double label immunofluorescence confirms cell-type specific patterns of 
immunoreactivity for GT-38 in CTE. (a-c) PHF1 and GFAP immunoreactivity showing a 
cluster of thorn-shaped astrocytes (arrow heads) that co-localize with GFAP. Adjacent 
neurons (arrows) do not co-localize with GFAP. (d-f) From the same region, a serial tissue 
section shows PHF1 immunoreactive neurons (arrows) that co-localize with MAP2 and 
nearby thorn-shaped astrocyte (arrow head) lacking MAP2 immunoreactivity. (g-l) While 
GT-38 positive cells fail to co-localize with GFAP, they demonstrate co-localization with 
MAP2, confirming their neuronal identity. Scale bars 50 µm. 
 
Figure S1. Double label immunofluorescence confirms perivascular astrocytes in a case 
of CTE. (a-c) PHF1 and GFAP immunoreactivity showing a cluster of thorn-shaped 
astrocytes that co-localize with GFAP positive cells. Cells with the morphological appearance 
of neurons fail to display any co-localization with GFAP immunoreactivity.  Scale bars 100 
µm. 
 
Figure S2. Double label immunofluorescence labelling in cases of ARTAG and AD. A 
case with ARTAG and low ADNC displaying (a-c) PHF1 immunoreactivity showing a 
cluster of TSA that fail to co-localize with MAP2. Note the single MAP2 positive / PHF1 
negative neuron within in the same field. (d-f) TSAs which are PHF1 immunoreactive and 
that co-localize with GFAP. (g-i) GFAP immunoreactive astrocytes in a region observed to 
have extensive PHF1 positive TSA on serial section, but without immunoreactivity to GT-38.  
Tissue from AD cases showing (j-l) PHF1 immunoreactive NFTs that do not co-localize with 
GFAP. (m-o) PHF1 positive neuron that co-localizes with MAP2. (p-r) GT-38 positive 
neuron that fails to co-localize with GFAP and, (s-u) a GT-38 positive neuron that co-
localizes with MAP2. Scale bars 50 µm. 
 
Figure S3. Dot-like immunoreactivity pattern in astrocytes stained for pS262 tau. (a-c) 
A subset of astrocytes showing less confluent and more punctate immunoreactivity for pS262 







Table 1. Demographic and Clinical Summary of Cases   





PMI Source Anatomical 
Region  
Examined 
1 CTE-NC 40s M Football CBD 7 hr Penn-CNDR Frontal 
2 CTE-NC 60s M Football CBD 3 hr Penn-CNDR Frontal 
3 CTE-NC  70s M Football DLB 18 hr Penn-CNDR Frontal 
4 CTE-NC 80s M Football FTLD-TDP 7 hr Penn-CNDR Frontal 
5 CTE-NC 60s M Boxing CTE 24 hr GTBIA Temporal 
6 CTE-NC  70s M Rugby CTE 12 hr GTBIA Insular 
7 CTE-NC 70s M Rugby AD 48 hr GTBIA Frontal 
8 CTE-NC 70s M Rugby Mixed AD/VaD 48 hr GTBIA Frontal 
9 CTE-NC  50s M Soccer CTE Unknown GTBIA Insular 
10 CTE-NC  80s M Soccer AD 24 hr GTBIA Frontal 
11 CTE-NC 50s M sTBI Remote TBI - No NDD 108 hr GTBIA Frontal 
12 CTE-NC 60s M sTBI Remote TBI - No NDD 24 hr GTBIA Temporal 
13 CTE-NC  70s M sTBI CTE 24 hr GTBIA Temporal 
14 CTE-NC 70s M Mild and 
Moderate TBI 
PDD 7.5 hr Penn-CNDR Angular 
   
15 ARTAG, PART 50s M No No NDD 80.5 hr GTBIA Frontal 
16 ARTAG, PART 80s M No PART 19 hr Penn-CNDR Temporal 
17 ARTAG, PART 70s M No No NDD 17hr Penn-CNDR Temporal 
18 PART 60s M No No NDD 11 hr Penn-CNDR Temporal 
19  ARTAG, Low ADNC 70s F No No NDD 18 hr Penn-CNDR Amygdala 
20 ARTAG, Low ADNC 70s F No No NDD 19 hr Penn-CNDR Amygdala 
21 ARTAG, Low ADNC 70s F No No NDD 18 hr Penn-CNDR Temporal 
22 ARTAG, Low ADNC 80s M No No NDD; CVD 7 hr Penn-CNDR Amygdala 
   
23 AD 60s M No AD 13.5 hr Penn-CNDR Angular 
24 AD 60s M No AD 5 hr Penn-CNDR Frontal 
25 AD 70s M No AD 4 hr Penn-CNDR Angular 
26 AD 70s M No AD 8.5 hr Penn-CNDR Angular 
27 AD 70s F No AD 11 hr Penn-CNDR Temporal 
28 AD 80s F No AD 6 hr GTBIA Cingulate 
   
29 FTLD-Tau 50s M No PiD 11 hr Penn-CNDR Temporal 
30 FTLD-Tau 60s M No PiD Unknown Penn-CNDR Temporal 
31 FTLD-Tau 70s M No PiD 22 hr Penn-CNDR Frontal 
32 FTLD-Tau 70s M No PiD 4 hr Penn-CNDR Angular 
33 FTLD-Tau 80s F No PiD 24 hr Penn-CNDR Frontal 
34 FTLD-Tau 50s M No PiD 10 hr Penn-CNDR Frontal 
35 FTLD-Tau 70s M No PSP 14 hr Penn-CNDR Frontal 
36 FTLD-Tau 80s M No PSP 23 hr Penn-CNDR Angular 
37 FTLD-Tau 70s M No PSP 23 hr Penn-CNDR Frontal 
38 FTLD-Tau 60s M No PSP 13 hr Penn-CNDR Angular 
39 FTLD-Tau 70s M No PSP 17 hr Penn-CNDR Temporal 
40 FTLD-Tau 70s M No PSP 19 hr Penn-CNDR Frontal 
41 FTLD-Tau 60s F No CBD 16 hr Penn-CNDR Temporal 
42 FTLD-Tau 70s M No CBD 11 hr Penn-CNDR Angular 
43 FTLD-Tau 50s M No CBD 41 hr Penn-CNDR Frontal 
44 FTLD-Tau 70s M No CBD 7.5 hr Penn-CNDR Temporal 
45 FTLD-Tau 80s M No CBD 11 hr Penn-CNDR Frontal 
46 FTLD-Tau 70s M No CBD 5 hr Penn-CNDR Frontal 
 
Key: PMI: Post-mortem interval; CTE-NC: Chronic traumatic encephalopathy neuropathologic change; CBD: Corticobasal degeneration; DLB: 
Dementia with Lewy bodies; FTLD-TDP: Frontotemporal lobar degeneration with TDP-43 inclusions; AD: Alzheimer’s Disease; VaD: Vascular 
dementia; TBI: Traumatic brain injury; NDD: Neurodegenerative disease; PDD: Parkinson Disease Dementia; ARTAG: Aging-related tau 
astrogliopathy; PART: Primary age-related tauopathy; ADNC: Alzheimer’s Disease neuropathologic change; CVD: Cerebrovascular disease; PiD: 
Pick’s Disease; PSP: Progressive supranuclear palsy; sTBI: Single moderate or severe TBI; GTBIA: Glasgow TBI Archive; Penn-CNDR: University 
of Pennsylvania Center for Neurodegenerative Disease Research 
 
Table 2. Antibody Details 






RD3 Three microtubule 
binding domain 
repeat (3R) tau 
Monoclonal (Ms) FA & Citrate 







RD4 Four microtubule 
binding domain 
repeat (4R) tau 
Monoclonal (Ms) FA & Citrate 
Buffer (pH 6.0) 
DAB: 1:400 Millipore Sigma 
(Burlington, MA) 
PHF1 Tau pS396 and 
pS404 
Monoclonal (Ms) Tris-EDTA 
Buffer (pH 8.0) 
DAB: 1:1000 
IF: 1:100 
Dr. Peter Davies (Albert 
Einstein College of 
Medicine, NY) 
CP13 Tau pS202 Monoclonal (Ms) Tris-EDTA 
Buffer (pH 8.0) 
DAB: 1:1000 Dr. Peter Davies (Albert 
Einstein College of 
Medicine, NY) 
Tau pS262 Tau pS262 Polyclonal (Rb) Citrate Buffer 
(pH 6.0) 
DAB: 1:1000 Millipore Sigma 
(Burlington, MA) 
AT100 Tau pS212 and 
pT214 
Monoclonal (Ms) Tris-EDTA 
Buffer (pH 8.0) 
DAB: 1:1000 ThermoFisher 
(Waltham, MA) 
Tau-C3 Caspase-cleaved tau, 
truncated at Asp421 
Monoclonal (Ms) Citrate Buffer 
(pH 6.0) 




Monoclonal (Ms) FA & Citrate 
Buffer (pH 6.0) 




Monoclonal (Ms) FA & Citrate 
Buffer (pH 6.0) 
DAB: 1:1000 




associated protein 2 
Polyclonal (Ck) Tris-EDTA 
Buffer (pH 8.0) 
IF: 1:200 Abcam (Cambridge, 
UK) 
GFAP Glial fibrillary acid 
protein, astrocyte-
specific 
Monoclonal (Rb) Tris-EDTA 
Buffer (pH 8.0) 
IF: 1:200 Abcam (Cambridge, 
UK) 
FA denotes 5 minutes of formic acid pre-treatment; Citrate versus Tris-EDTA buffer denotes pretreatment with 
heat/pressure submerged in respective buffer. DAB: 3,3′-Diaminobenzidine visualization protocol;  IF: 
immunofluorescence protocol; Rb: rabbit; Ms: mouse; Ck: Chicken. 
 
 
Table 3. Tau Phenotype Semi-Quantitative Scores – 3R, 4R and Conformation 
3R 4R GT-7 GT-38 Case TSA NFT TSA NFT TSA NFT TSA NFT 
1 – CTE-NC - ++ +++ +++ - ++ - ++ 
2 - CTE-NC - ++ +++ +++ - ++ - ++ 
3 - CTE-NC - +++ +++ +++ - +++ - +++ 
4 - CTE-NC + ++ +++ +++ - ++ + ++ 
5 - CTE-NC - +++ +++ +++ - +++ - +++ 
6 - CTE-NC  - +++ +++ +++ - +++ - +++ 
7 - CTE-NC + +++ +++ +++ - +++ - +++ 
8 - CTE-NC - +++ +++ +++ + +++ + +++ 
9 - CTE-NC x x x x x x x x 
10 - CTE-NC - +++ +++ +++ - +++ - +++ 
11 - CTE-NC x x x x - +++ - +++ 
12 - CTE-NC - ++ ++ ++ - ++ - ++ 
13 - CTE-NC - +++ ++ ++ + +++ + +++ 
14 - CTE-NC - +++ +++ +++ + ++ - ++ 
 
 TSA NFT TSA NFT TSA NFT TSA NFT 
15 - ARTAG, PART x x x x - +++ - +++ 
16- ARTAG, PART - + +++ +++ - +++ - +++ 
17- ARTAG, PART - +++ +++ +++ - +++ - +++ 
18 - PART N/A ++ N/A ++ N/A ++ N/A ++ 
19 - ARTAG, Low AD-
NC 
- +++ +++ +++ - ++ - +++ 
20 - ARTAG, Low AD-
NC 
+ ++ +++ +++ + +++ + +++ 
21 - ARTAG, Low AD-
NC 
- +++ +++ +++ - +++ - +++ 
22 - ARTAG, Low AD-
NC 
- +++ +++ +++ - +++ - +++ 
 
 NFT NFT NFT NFT 
23 - AD +++ +++ +++ +++ 
24 - AD +++ +++ +++ +++ 
25 - AD +++ +++ +++ +++ 
26 - AD +++ +++ +++ +++ 
27 - AD +++ +++ +++ +++ 


















29 - PiD +++ +++ - ++ - - - - 
30 - PiD +++ N/A - N/A - N/A - N/A 
31 - PiD +++ +++ - - - - - - 
32 - PiD +++ N/A - N/A - N/A - N/A 
33 - PiD +++ N/A - N/A - N/A - N/A 
34 - PiD +++ +++ - - - - - - 
 Tufted Astrocytes Tufted Astrocytes Tufted Astrocytes Tufted Astrocytes 
35 - PSP - +++ - - 
36 - PSP - +++ - - 
37 - PSP - ++ - - 
38 - PSP - +++ - - 
39 - PSP - ++ - - 
40 - PSP - +++ - - 
 Astrocytic Plaques Astrocytic Plaques Astrocytic Plaques Astrocytic Plaques 
41 - CBD - +++ - - 
42 - CBD - +++ - - 
43 - CBD - +++ - - 
44 - CBD - +++ - - 
45 - CBD - +++ - - 
46 - CBD - +++ - - 
Semi-quantitative Scoring: - absent, or nearly absent (≤5% concordance with extent of PHF1); + minimal (5-30% concordance); ++ 
moderate (30-70% concordance); +++ extensive (>70% concordance); X: No immunoreactivity   
CTE-NC: Chronic traumatic encephalopathy neuropathologic change; TSA: thorn-shaped astrocytes; NFT: neurofibrillary tangles; 
ARTAG: Aging-related tau astrogliopathy; PART: Primary age-related tauopathy; AD-NC: Alzheimer’s Disease neuropathologic 
change; AD: Alzheimer’s Disease; FTLD-Tau: Frontotemporal lobar degeneration tauopathies; N/A: not applicable. 
 
 
Table 4. Tau Phenotype Semi-Quantitative Scores – Post-Translational Modifications 
PHF-1 CP13 AT100 pS262 Tau-C3 Case TSA NFT TSA NFT TSA NFT TSA NFT TSA NFT 
1 - CTE-NC +++ +++ +++ +++ + +++ +++ +++ - + 
2 - CTE-NC +++ +++ +++ +++ +++ +++ +++ +++ - + 
3 - CTE-NC +++ +++ +++ +++ +++ +++ +++ +++ - - 
4 - CTE-NC +++ +++ +++ +++ ++ ++ +++ +++ - ++ 
5 - CTE-NC +++ +++ +++ +++ +++ +++ + +++ - + 
6 - CTE-NC +++ +++ +++ +++ +++ +++ ++ +++ - + 
7 - CTE-NC +++ +++ +++ +++ +++ +++ + +++ - + 
8 - CTE-NC +++ +++ +++ +++ +++ +++ ++ +++ - + 
9 - CTE-NC +++ +++ +++ +++ +++ +++ - + x x 
10 - CTE-NC +++ +++ +++ +++ +++ +++ ++ +++ + ++ 
11 - CTE-NC +++ +++ +++ +++ +++ +++ - +++ - + 
12 - CTE-NC +++ +++ +++ +++ ++ +++ - +++ - + 
13 - CTE-NC +++ +++ +++ +++ +++ +++ ++ +++ - ++ 
14 - CTE-NC +++ +++ +++ +++ +++ +++ +++ +++ - + 
 
 TSA NFT TSA NFT TSA NFT TSA NFT TSA NFT 
15 - ARTAG, PART +++ +++ +++ +++ +++ +++ + ++ + ++ 
16.- ARTAG, PART +++ +++ +++ +++ +++ +++ ++ +++ - +++ 
17.- ARTAG, PART +++ +++ +++ +++ +++ +++ + +++ - + 
18 - PART N/A +++ N/A +++ N/A ++ N/A ++ N/A - 
19 - ARTAG, Low AD-NC +++ +++ +++ +++ +++ +++ +++ +++ - + 
20 - ARTAG, Low AD-NC +++ +++ +++ +++ +++ +++ +++ +++ - ++ 
21 - ARTAG, Low AD-NC +++ +++ +++ +++ +++ +++ ++ +++ - - 
22 - ARTAG, Low AD-NC +++ +++ +++ +++ +++ +++ +++ +++ - - 
 
 NFT NFT NFT NFT NFT 
23 - AD +++ +++ ++ +++ ++ 
24 - AD +++ +++ +++ +++ ++ 
25 - AD +++ +++ +++ +++ + 
26 - AD +++ +++ +++ +++ + 
27 - AD +++ +++ +++ +++ ++ 






















29 - PiD +++ +++ +++ +++ +++ +++ ++ + ++ - 
30 - PiD +++ N/A +++ N/A +++ N/A - N/A ++ N/A 
31 - PiD +++ +++ +++ +++ +++ +++ - - - - 
32 - PiD +++ N/A +++ N/A +++ N/A - N/A - N/A 
33 - PiD +++ N/A +++ N/A +++ N/A - N/A - N/A 
34 - PiD +++ +++ +++ +++ +++ +++ - - - - 
 Tufted   
Astrocytes 
Tufted   
Astrocytes 
Tufted Astrocytes Tufted Astrocytes Tufted Astrocytes 
35 - PSP +++ +++ ++ ++ + 
36 - PSP +++ +++ +++ + +++ 
37 - PSP +++ +++ +++ + - 
38 - PSP +++ +++ +++ + - 
39 - PSP +++ +++ ++ - - 
40 - PSP +++ +++ +++ ++ - 
 Astrocytic 
Plaques 






41 - CBD +++ +++ + + - 
42 - CBD +++ +++ +++ - - 
43 - CBD +++ +++ ++ - - 
44 - CBD +++ +++ ++ ++ - 
45 - CBD +++ +++ +++ + - 
46 - CBD +++ +++ +++ +++ - 
Semi-quantitative Scoring: - absent, or nearly absent (≤5% concordance with extent of PHF1); + minimal (5-30% concordance); ++ moderate 
(30-70% concordance); +++ extensive (>70% concordance); X: No immunoreactivity   
CTE-NC: Chronic traumatic encephalopathy neuropathologic change; TSA: thorn-shaped astrocytes; NFT: neurofibrillary tangles; ARTAG: 
Aging-related tau astrogliopathy; PART: Primary age-related tauopathy; AD-NC: Alzheimer’s Disease neuropathologic change; AD: 
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